Exosomes News and Research

RSS

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form.

11 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Study reveals mechanical forces that drive epithelial wound healing

A collaborative study led by scientists from the Mechanobiology Institute at the National University of Singapore has revealed the mechanical forces that drive epithelial wound healing in the absence of cell supporting environment. This research was published in Nature Communications in January 2015.

9 Feb 2015

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Does the blood of Ebola virus disease survivors contain antibodies and immune cells that could help doctors fight Ebola infections in other people?

9 Feb 2015

Artificial mini-organism: An alternative to animal testing

No one wishes to dispense with the blessings of modern medicine, which took away the dread of many diseases. The flipside of the coin: To ensure that effective and safe medications are available, experiments on animals in research laboratories are indispensable.

9 Feb 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

Purdue University researchers find promising way to treat late-stage prostate cancer

Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds.

28 Jan 2015

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

Porvair Sciences releases 2015 catalogue of tissue culture plastics and epigenetic consumables

Porvair Sciences has released a new 2015 catalogue that describes its popular range of high quality tissue culture treated plastics and consumable products for Epigenetics.

From Chromatrap® - Porvair Sciences Ltd 22 Dec 2014

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.

16 Dec 2014

Penn study has implications for developing new cell-based treatments for skin disease

As the main component of connective tissue in the body, fibroblasts are the most common type of cell. Taking advantage of that ready availability, scientists from the Perelman School of Medicine at the University of Pennsylvania, the Wistar Institute, Boston University School of Medicine, and New Jersey Institute of Technology have discovered a way to repurpose fibroblasts into functional melanocytes, the body's pigment-producing cells.

16 Dec 2014

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal.

11 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Findings may guide doctors to choose better therapies for patients with myeloma

The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology by researchers at Dana-Farber Cancer Institute.

7 Dec 2014

Cytation™ 5 Cell Imaging Multi-Mode Reader to be introduced by BioTek at ASCB 2014

Join BioTek Instruments as they introduce the Cytation™ 5 Cell Imaging Multi-Mode Reader at the ASCB 2014 Conference and Exhibition to be held December 6-10 in Philadelphia, Pennsylvania. BioTek’s “Think Possible” philosophy is reflected in their microplate-based imaging, detection, liquid handling and automation solutions and the company will showcase their newest innovations at Booth #349.

3 Dec 2014

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

The FK506-binding protein 51 (FKBP51) is an established risk factor for stress-related psychiatric disorders such as major depression. Drug discovery for FKBP51 has been hampered by the inability to pharmacologically differentiate against the very similar functional counterplayer FKBP52.

3 Dec 2014

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Surprisingly, even with decades of cryopreservation research, little progress has been made in the way frozen biospecimens are thawed. It’s still very common for researchers and clinicians to thaw cells and other frozen biological samples in a variety of manual ways ...

25 Nov 2014

Exosomes News and Research

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Study reveals mechanical forces that drive epithelial wound healing

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Artificial mini-organism: An alternative to animal testing

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Purdue University researchers find promising way to treat late-stage prostate cancer

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Porvair Sciences releases 2015 catalogue of tissue culture plastics and epigenetic consumables

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Penn study has implications for developing new cell-based treatments for skin disease

Potential new active substances for treating dengue virus

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Findings may guide doctors to choose better therapies for patients with myeloma

Cytation™ 5 Cell Imaging Multi-Mode Reader to be introduced by BioTek at ASCB 2014

SAFit-ligands provide foundation for novel treatment of stress-related psychiatric disorders

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms